CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-METHYLTRANSFERASE INHIBITORS AND INTENDED FOR THIS COMPOSITION Russian patent published in 2021 - IPC A61K31/00 A61K31/198 A61K31/375 A61K47/12 A61K9/08 A61P25/16 

FIELD: medicine.

SUBSTANCE: group of inventions refers to a pharmaceutically acceptable composition for treating a neurological movement disorder containing from 2.5 % to 7 % by weight of levodopa, from 0.5 % to 2 % by weight of carbidopa, from 5 % to 18 % by weight of arginine and from 0.25 % to 3 % by weight of ascorbic acid or its pharmaceutically acceptable salt, where pH of said composition ranges from 9.1 to 9.8 at 25 °C. Group of inventions also relates to a method of treating a neurological disorder in a patient in need thereof, involving administering said composition to said patient.

EFFECT: group of inventions provides higher stability of levodopa due to inclusion of carbidopa, ascorbic acid or its pharmaceutically acceptable salts into the composition, which prevent oxidation of levodopa, id est chemical stabilizers, and arginine, which is capable of forming salts of carbidopa and levodopa.

10 cl, 6 dwg,19 tbl, 9 ex